

Inova Advanced Lung Disease Center Research Activities

AUGUST 2022 (updated 08/09/2022 by SN)

Inova ALD and Transplant Program Academic Accomplishments 2022

Editorials

Submitted papers, reviews and chapters submitted or in revision

1. Schwartz D. et al (124 authors including Drew, Merte and SDN). Host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis. (letter) submitted to Nature Genetics
2. **Aryal S, Ahmad K, Nathan SD**. Group 3 PH: Clinical Features and Treatment: For Encyclopedia of Respiratory Medicine, 2nd Edition Medicine being published by Elsevier. Resubmitted 12/18/2019
3. Kenneth Risner, Katie V. Tieu, Yafei Wang, Allison Bakovic, Farhang Alem, Nishank Bhalla, Steven D. Nathan, Daniel E. Conway, Paul Macklin, Aarthi Narayanan, Farhang Alem. Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion. Submitted to Frontiers in Virology 11/19/2021
4. Gustavo A. Heresi, Bonnie B. Dean, Howard Castillo, Henry F. Lee, Peter Classi, Dana Stafkey-Mailey, Alexander Kantorovich, Kellie Morland, Margaret R. Sketch, Benjamin S. Wu, **Christopher S. King**. Identifying Patients With Group 3 Pulmonary Hypertension Using an Administrative Claims Database. Submitted to Annals ATS 01/14/2021
5. Bernardo, Roberto; Lu, Di; Ramirez, Ramon; Hedlin, Haley; Kawut, Steven; Bull, Todd; De Marco, Teresa; Ford, H.; Grinnan, Dan; Klinger, James; McConnell, John; Berman-Rosenzweig, Erika; **Shlobin, Oksana**; Zamanian, Roham; De Jesus Perez, Vinicio. Hispanic ethnicity and social determinants of health in pulmonary arterial hypertension: The Pulmonary Hypertension Association Registry". Submitted to Chest 2021
6. Sahay S, Balasubramanian V, Memon H, Poms A, Bossone E, Highland K, Kay D, Levine D, Mullins C, Melendres-Groves L, Mathai S, Soto F, **Shlobin OA**, Elwing J. Utilization of Risk Assessment Tools in Management of PAH: An International PAH Provider Survey. Submitted to Chest 2021
7. Minhas J, Narasimhal S; Bull T, DeMarco T, McConnell J, Lammi M, Thenappan T, Feldman J, Sager J, Badesch D, Ryan J, Grinnan D, Zwicke D, Horn E, Elwing J, Moss J, Eggert M, **Shlobin OA**, Frantz R, Bartolome S, Mathai S, Mazimba S, Pugliese S, Al-Naamani N. Health Related Quality of Life and Hospitalizations In Chronic Thromboembolic Pulmonary Hypertension Versus Idiopathic Pulmonary Arterial Hypertension: An Analysis from the Pulmonary Hypertension Association (PHAR). Submitted to Pulmonary Circulation August 2021.
8. Ananth V. Charya, **Adam Cochrane**, Ileana L. Ponor, Deborah Levine, Mary Philogene, Yi-Ping Fu, Moon K. Jang, Hyesik Kong, Pali Shah, Joby Matthews, Helen Luikart, Kiran Khush, Gerald Berry, Charles Marboe, Aldo Iacono, Jonathan B. Orens, **Steven Nathan**, Sean Agbor-Enoh. Clinical Features and Allograft Failure Rates of Pulmonary Antibody-Mediated Rejection Categories. Rejected by the Blue Journal 11/29//2021
9. Michael Keller, Song Yang, Lucia Ponor, **Adam Cochrane**, Mary Philogene, Errol Bush, Pali Shah, Joby Matthews, **Anne W Brown**, Hyesik Kong, Ananth Charya, Helen Luikart, **Steven D. Nathan**, Kiran K. Khush, Moon Jang, Sean Agbor-Enoh. Preemptive treatment of deNOVO Donor-Specific Antibodies in lung transplant patients decreases the risk of allograft failure. To be submitted

10. Pelljto AL, **Nathan SD**, Schwartz (116 authors). Idiopathic pulmonary fibrosis is associated with common genetic variants and a limited number of rare variants. Submitted to Lancet Res Med June 12th, 2022

CONSENSUS STATEMENTS (submitted)

1. Daniela Pasero, Alain Vuylsteke, **Christopher King**, Nicolas Lees, Sabina Martelli, Philippe Montravers, Roberto Mosca, Michael S. Mulligan, Sven-Erik Richsten, Peter Von Homeyer, Bertrand Rozec, Vito Marco Ranieri, Thomas Weig, Eric de Waal, Dominik Hoechter, Vera von Dossow, Nandor Marczin, Lars Algotsson. International Consensus Recommendations for Anesthetic and Intensive Care Management of Lung Transplantation: An EACTA, SCA, ISHLT, ESOT, ESTS, and AST Approved document
2. Nandor Marczin, Eric de Waal, Bessie Kachulis, Christopher King, Morgan Le Guen, Marc Fischler, Marc leone M, Joseph Bekkers, Andreas Espinoza, Matthias Hommel, Michael S Mulligan, Barbora Parizkova; Vincent Valentine, Sebastian Zenz, Goran Dellgren, Oliver Bastien, Duane Davis, Peter von Homeyer, Aidan Burrell, Dirk Van Raemdonck, Andre Simon, Vera von Dossow, Dominik Hoechter, Arne Neyrinck, Peter Slinger, Franco Valenca. General Intraoperative Management in Lung Transplantation. JHLT 2021
3. Franck F Rahaghi; Vivien M Hsu; Robert J Kaner; Maureen D Mayes; Ivan O Rosas; Rajan Sagar; Richard M Silver; Virginia D Steen; Mary E Streck; Elana J Bernstein; Nitin Bhatt; Flavia V Castelino; Lorinda Chung; Robyn T Domsic; Kevin R Flaherty; Nishant Gupta; Bashar Kahaleh; Fernando J Martinez; Lee E Morrow; Teng Moua; Nina Patel; **Oksana A Shlobin**; Brian D Southern; Elizabeth R Volkmann; Dinesh Khanna. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. Submitted to Respiratory Research July 2021.
4. Sylvia M. Nikkho, Manuel J. Richter, Eric Shen, Steven H. Abman, Katerina Antoniou, Jonathan Chung, Peter Fernandes, Paul Hassoun, Howard M. Lazarus, Horst Olschewski, Lucilla Piccari, Mitchell Psotka, Rajan Sagar, **Oksana Shlobin**, Norman Stockbridge, Patrizio Vitulo, Carmine Dario Vizza, S. John Wort, and **Steven D. Nathan**. Clinical significance of pulmonary hypertension in interstitial lung disease: A Consensus Statement from The Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension. Submitted to Pulmonary Circulation June 10th, 2022

ORIGINAL RESEARCH MANUSCRIPTS:

PUBLISHED

1. Raghu G, Hamblin MJ, **Brown AW**, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Burgess T, Kamath N, Donaldson F, Richeldi L. Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study Respir Res. 2022 May 21;23(1):129. doi: 10.1186/s12931-022-02047-0.
2. Chakravorty S, **Cochrane AB**, **Psotka MA**, **Regmi A**, **Marinak L**, **Thatcher A**, **Shlobin OA**, **Brown AW**, **King CS**, **Ahmad K**, **Khangoora V**, **Singhal A**, **Nathan SD**, **Aryal S**. CMV Infection Following mRNA SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplant

Direct. 2022 Jun 10;8(7):e1344. doi: 10.1097/TXD.0000000000001344. PMID: 35706606; PMCID: PMC9191559.

3. Gerard J. Criner , Frederick M. Lang, Robert L. Gottlieb, Kusum S. Mathews , Tisha S. Wang , Todd W. Rice, Deepu Madduri, Shashi Bellam, Robert Jeanfreau, Amy H. Case , Marilyn K. Glassberg, George Marshall Lyon, **Kareem Ahmad**, Robert Mendelson, J. Michael DiMaio, MaryAnn P. Tran , Cedric W. Spak, Jamil A. Abbasi, Steven G. Davis, Shekhar Ghamande, Steven Shen, Lisa Sherman ,Simon Lowry. Anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial
4. Michael B. Keller, Rohan Meda, Sheng Fu, Kai Yu, Moon Kyoo Jang., Ananth Charya, Gerald J. Berry, Charles Marboe, Hyesik Kong, Helen Luikart, Ileana L. Ponor, Pali D. Shah, Kiran K Khush, , **Steven D. Nathan**, Sean Agbor-Enoh. Comparison of Donor-Derived Cell-Free DNA Between Single vs. Double Lung Transplant Recipients. *Am J Transplant.* 2022;00:1–7
5. Rahaghi FR, Balasubramanian VP, Bourge RC, Burger CD, Chakinala MM, Eggert MS, Elwing JM, Feldman J, **King C**, Klinger JR, Mathai SC, McConnell JW, Palevsky HI, Restrepo-Jaramillo R, Safdar Z, Sager JS, Sood N, Sulica R, White EJ, Hill NS. Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat. *Pulm Circ.* 2022; 12(2): e12055.
6. Heresi G, Dean BB, Castillo H, Lee HF, Classi P, Stafkey-Mailey D, Kantrovich A, morland K, Sketch MR, Wu b, **King CS**. Identifying Patients with Group 3 Pulmonary Hypertension Associated with COPD or ILD Using an Administrative Claims Database. *Lung.* 2022. (e-pub)
7. Gupta R, Baughman RP, **Nathan SD**, Wells AU, Kouranos V, Alhamad EH, Culver DA, Barney J, Carmona EM, Cordova FC, Huitema M, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Price LC, Wort SJ, **Shlobin OA**. Value of the Six-Minute Walk Test in Sarcoidosis Associated Pulmonary Hypertension: Results from an International Registry. *Respiratory Medicine* 196 (2022) 106801
8. Abhimanyu Chandel, Jean Pastre, Solène Valery, **Christopher S. King, Steven D. Nathan**. Addition of functional parameters to a simple multidimensional index augments survival prediction in idiopathic pulmonary fibrosis. *Thorax* 2022;0:1–8. doi:10.1136/thoraxjnl-2021-218440
9. Marloes Huitema, Marco C Post; Jan C Grutters; Athol U Wells; Vasilis Kouranos; **Oksana Shlobin; Steven D Nathan**; Daniel A Culver; Joseph Barney; Rohit Gupta; Eva Carmona; Esam H Alhamad; Mary B Scholand; Marlies Wijsenbeek; Sivagini Ganesh; Elyse E Lower; Peter J Engel; Robert P Baughman. Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients, a multi-national study. *Sarcoidosis Vasc Diffuse Lung Dis.* 2022;38(4):e2021032. doi: 10.36141/svldd.v38i4.11376. Epub 2022 Jan 13. PMID: 35115744
10. **Nathan SD**, Tapson VF, Elwing J, Rischard F, Mehta J, Shapiro S, Shen E, Deng C, Smith P, Waxman A. Efficacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to parenchymal lung disease in the INCREASE trial. Steven D. Nathan, Victor F. Tapson, Jean Elwing, Franz Rischard, Jinesh Mehta, Shelley Shapiro, Eric Shen, Lisa Edwards, Peter Smith, Aaron Waxman. Efficacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to parenchymal lung disease in the INCREASE trial. *Am J Respir Crit Care Med.* 2022 Jan 15;205(2):198-207. doi: 10.1164/rccm.202107-1766OC. PMID: 34767495
11. Michael Keller, Junfeng Sun, Cedric Mutebi, Pali Shah, Deborah Levine, **Shambhu Aryal**, Aldo Iacono, Irina Timofte, Joby Mathew, Anu Varghese, Cassandra Giner, Sean Agbor-Enoh. Donor-derived cell-free DNA as a compositemarker of acute lung allograft dysfunction in

- clinical care *J Heart Lung Transplant* 2022. 000;000:1–9
12. **King CS**, Mannem H, Kukreja J, **Aryal S**, **Tang D**, Singer JP, Bharat A, Behr J, **Nathan SD**. Lung Transplantation of COVID-19 patients: How I do it. *CHEST* 2022; 161(1):169-178
 13. Michael Keller, Cedric Mutebi, Pali Shah, Deborah Levine, **Shambhu Aryal**, Aldo Iacono, Irina Timofte, Joby Mathew, Anu Varghese, Cassandra Giner, Sean Agbor-Enoh. Biological Variation of Donor-Derived Cell-Free DNA in Stable Lung Transplant Recipients. *JALM* 2022;00:0 1-9
 14. Michael Keller, Errol Bush, Joshua M. Diamond, Pali Shah, Joby Matthews, **Anne W Brown**, Junfeng Sun, Irina Timofte, Hyesik Kong, Ilker Tunc, Helen Luikart, Aldo Iacono, **Steven Nathan**, Kiran K. Khush, Jonathan Orens, Moon Jang⁴, Hannah A Valentine, Sean Agbor-Enoh. Use of Donor-Derived-Cell-Free DNA as a Marker of Early Allograft Injury in Primary Graft Dysfunction (PGD) to Predict the Risk of Chronic Lung Allograft Dysfunction (CLAD). *J Heart Lung Transplant*. 2021 Feb 20:S1053-2498(21)02180-X. doi: 10.1016/j.healun.2021.02.008. Online ahead of print.
 15. Lauren C. Testa, Yvon Jule, Linnea Lundh, Karine Bertotti, Melissa A. Merideth, Kevin J. O'Brien, Olivier Jule, **Steven D. Nathan**, Drew C. Venuto, Souheil El-Chemaly, May Christine V. Malicdan, Bernadette R. Gochuico. Automated Quantification of Pulmonary Fibrosis in Human Histopathology Specimens. *Front. Med.*, 15 June 2021 | <https://doi.org/10.3389/fmed.2021.607720>
 16. Jang MK, Tunc I, Berry GJ, Marboe C, Kong H, Keller MB, Shah PD, Timofte I, Brown AW, Ponor IL, Mutebi C, Philogene MC, Yu K, Iacono A, Orens JB, **Nathan SD**, Agbor-Enoh S. Donor-derived cell-free DNA accurately detects acute rejection in lung transplant recipients, a multicenter cohort study. *J Heart Lung Transplant*. 2021 Apr 24:S1053-2498(21)02281-6. doi: 10.1016/j.healun.2021.04.009. Online ahead of print.
 17. **Nathan SD**, Cottin V, Behr J, Hoepfer MM, Martinez F, Corte T, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Ley-Zaporozhan J, Müller-Lisse GU, Scholle FD, Brueggenwerth G, Busse D, Nikkho S, Wells AU. Impact of lung morphology on clinical outcomes with riociguat in the RISE-IIP study. *J Heart Lung Transplant* 2021;40:494–503
 18. Chung JH, Adegunsoye A, **Cannon B**, Vij R, Oldham JM, **King CS**, Montner SM, Thirkateh P, **Barnett SB**, Karwoski RA, Bartholmai BJ, Streck ME, **Nathan SD**. Differentiation of idiopathic pulmonary fibrosis from connective tissue disease related interstitial lung disease using quantitative imaging. *J. Clin. Med.* 2021, 10, 2663. <https://doi.org/10.3390/jcm10122663>
 19. Baughman RP, **Shlobin OA**, Gupta R, Engel PE, Stewart J, Lowere EE, Rahaghi F, Zeigler J, **Nathan SD**. Riociguat for Sarcoidosis Associated Pulmonary Hypertension: Results of a One Year Double Blind, Placebo Controlled Trial. *CHEST* 2022; 161(2):448-457
 20. Amisha V. Barochia, Maryann Kaler, **Nargues Weir**, Elizabeth M. Gordon, Debbie M. Figueroa, **Merte Lemma WoldeHanna**, Maureen Sampson, Alan T. Remaley, Geraldine Grant, **Scott D. Barnett**, **Steven D. Nathan**, and Stewart J. Levine MR. Spectroscopy Identifies that Serum Levels of Small HDL Particles are Negatively Correlated with Death or Lung Transplantation in Idiopathic Pulmonary Fibrosis. *Eur Respir J.* 2021 Jul 21:2004053. doi: 10.1183/13993003.04053-2020. Online ahead of print. PMID: 34289973
 21. **Steven D. Nathan**, Juergen Behr, Vincent Cottin, Lisa Lancaster, Peter Smith, CQ Deng, Natalie Pearce⁵, Heidi Bell, Leigh Peterson, Kevin R. Flaherty. Study Design and Rationale for the TETON Phase 3, Randomized, Controlled Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis. *BMJ Open Res* 2022;9:e001310. doi:10.1136/bmjresp-2022-001310

22. Katrina Bazemore, Nitipong Permpalung, Joby Mathew, **Merte Lemma**, Betelihim Haile, Robin Avery, Hyesik Kong, Moon Kyoo Jang, Temesgen Andargie, Shilpa Gopinath, **Steven D. Nathan**, **Shambhu Aryal**, Jonathan Orens, Sean Agbor-Enoh, Pali Shah. Elevated Cell Free DNA in Respiratory Viral Infection and Associated Lung Allograft Dysfunction. *Am J Transplant*. 2022;00:1-11
23. Rahagi F, Kolaitis N, Adegunsoye A, de Andrade J, Flaherty K, Lancaster L, Lee J, Levine D, Preston I, Safdar Z, Saggarr R, Sahar S, Scholand MB, **Shlobin OA**, Zisman D, **Nathan SD**. Screening strategies for pulmonary hypertension in patients with interstitial lung disease: A multidisciplinary delphi study. *Chest*. 2022 ;162(1):145-155
24. **Christopher S. King**, Kevin R. Flaherty, Marilyn K. Glassberg, Lisa Lancaster, Ganesh Raghu, Jeffrey J. Swigris, Rahul G. Argula, Rosemarie A. Dudenhofer, Neil A. Ettinger, Jeremy Feldman; Shilpa Johri, P Fernandes, M. Pharm. Ed Parsley; Parag Shah; **Steven D. Nathan**. A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen. *Ann Am Thorac Soc*. 2022 Apr;19(4):594-602. doi: 10.1513/AnnalsATS.202107-864OC.

ORIGINAL RESEARCH MANUSCRIPTS:

ACCEPTED or EPUB

1. Sahay S, Balasubramanian V, Memom H, Poms A, Bossone E, Highland K, Kay D, Levine D, Mullin C, Melendres-Groves L, Matha S, Soto F, Shlobin OA, Elwing JM. Utilization of Risk Assessment Tools in Management of PAH: A PAH Provider Survey. Accepted to *Pulmonary Circulation* 2022.
2. Bernardo RJ, Lu D, Ramirez R, Hedlin H, Kawut S, Bull T, De Marco T, Ford HJ, Grinnan D, Klinger JR, McConnell JW, Berman-Rosenzweig E, **Shlobin OA**, Zamanian RT, de Jesus Perez VA. Hispanic ethnicity and social determinants of health in pulmonary arterial hypertension: The Pulmonary Hypertension Association Registry. Accepted to *Annals of ATS* 2022.
3. Rahatgi F, **King C**, et al. Delphi Consensus Recommendation for Optimization of Pulmonary Hypertension Therapy Focusing On Switching from a Phosphodiesterase 5 Inhibitor to Riociguat. Accepted to *Pulm Circ* Jan 18 2022
4. Huitema M, Post M, Grutters J, Wells A, Kouranos V, Shlobin OA, Nathan SD, Culver D, Gupta R, Carmona E, Scholand M, Wijsenbeek M, Ganesh S, Lower E, Engel P, Baughman R. Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients, a multi-national study. Accepted to *Sarc Vasc and Diffuse Lung Dis* 12/21.
5. Vizza CD, Lang IM, Badagliacca R, Benza RL, Rosenkranz S, Adir Y, Andreassen AK, Balasubramanian V, Bartolome S, Blanco I, Bourge RC, Carlsen J, Camacho REC, D'Alto M, Farber HW, Frantz RP, Ford HJ, Ghio S, Gomberg-Maitland M, Naeije R, Orfanos SE, Oudiz RJ, Perrone SV, Shlobin OA, Simon MA, Torres F, Wang KY, White RJ, Yoacoub MH, Liu Y, Golden G, Matsubara H. Aggressive Afterload Lowering to Improve the RV: A New Target for Medical Therapy in PAH? Accepted to *AJRCC* 11/21.
6. Minhas J, Narasimma SP, Bull T, De Marco T, McConnell JW, Lammi MR, Thenappan T, Feldman J, Sager J, Badesch D, Ryan JJ, Grinnan D, Zwicke D, Horn E, Elwing JM, Moss JE, Eggert M, Shlobin OA, Frantz R, Bartolome S, Mathai SC, Mazimba S, Pugliese S, Al-Naamani N on behalf of the PHAR investigators. Health related quality of life and hospitalizations in Chronic Thromboembolic Pulmonary Hypertension versus Idiopathic Pulmonary Arterial Hypertension: An

analysis from the Pulmonary Hypertension Association Registry (PHAR). *Pulmonary Circulation* October 2021. doi:10.1177/20458940211053196

7. Abhimanyu Chandel, **Nathan SD**, **King C** et al. Association of D-dimer and fibrinogen with hypercoagulability in COVID-19 requiring extracorporeal membrane oxygenation. Accepted to the *Journal of Intensive Care Medicine* 01/06/2021.
8. Na'ama Avitzur, Elizabeth M. Noth, Mubasiru Lamidi, **Steven D. Nathan**, Harold R. Collard, Alison M. DeDent, Neeta Thakur, Kerri A. Johannson. Environmental Health, Disease Severity, and Anti-fibrotic Use in Patients with Idiopathic Pulmonary Fibrosis. Accepted to *Thorax* 11/26/2021

CONSENSUS STATEMENTS (Published or accepted)

1. Dana McGlothlin, John Granton, Walter Klepetko, Maurice Beghetti, Erica Berman-Rosenzweig, Paul Corris, Teresa De Marco, Evelyn Horn, Manreet Kanwar, Karen McRae, Antonio Roman, Ryan Tedford, Roberto Badagliaacca, Sonja Bartolome, Raymond Benza, Marco Caccamo, Rebecca Cogswell, Celine Dewachter, Laura Donahoe, Elie Fadel, Harrison Farber, Jeffrey Feinstein, Veronica Franco, Robert Frantz, Michael Gatzoulis, Choon Hwa (Anne) Goh, Marco Guazzi, Georg Hansmann, Stuart Hastings, Paul Heerdt, Anna Hemnes, Antioine Herpain, Chih-Hsin Hsu, Kim Kerr, Nicholas Kolaitis, Jasleen Kukreja, Michael Madani, Stuart McCluskey, Michael McCulloch, Bernhard Moser, Manchula Navaratnam, Goran Radegran, Cara Reimer, Laurent Savale, Oksana A Shlobin, Jana Svetlichnaya, Keith Swetz, Jessica Tashjian, Thenappan Thenappan, C. Dario Vizza, Shawn West, Warren Zuckerman, Andreas Zuckermann. ISHLT consensus document for peri-operative management of patients with pulmonary hypertension. Accepted to *JHLT* 2022
2. Savale L, Huitema M, **Shlobin O**, Kouranos V, Wells AU, Humbert M, **Nathan SD**, Nunes H, Gupta R, Grutters JC, Culver D, Post MC, Oullette D, Lower EE, Baughman RP. Statement on the Diagnosis and Management of Sarcoidosis-Associated Pulmonary Hypertension. *Eur Respir Rev* 2022; 31: 210165 [DOI: 10.1183/16000617.0165-2021].
3. Vincent Cottin, Sara Tomassetti, Claudia Valenzuela, Simon Walsh, Katerina Antoniou, Francesco Bonella, Kevin Brown, Harold Collard, Tamera J Corte, Kevin Flaherty, Kerri Johannson, Martin Kolb, Michael Kreuter, Yoshikazu Inoue, Gisli Jenkins, Joyce Lee, David Lynch, Toby Maher, Fernando Martinez, Maria Molina Molina, Jeff Myers, **Steven D Nathan**, Venerino Poletti, Sylvia Quadrelli, Ganesh Raghu, Claudia Ravaglia, Sujeet Rajan, Martine Remy-Jardin, Elisabetta Renzoni, Luca Richeldi, Paolo Spagnolo, Lauren Troy, Marlies Wijsenbeek, Kevin Wilson, Wim Wuyts, Athol U Wells, Christopher Ryerson. Integrating clinical probability into the diagnostic approach to idiopathic pulmonary fibrosis : An international working group perspective. *Am J Respir Crit Care Med.* 2022 Aug 1;206(3):247-259. doi: 10.1164/rccm.202111-2607PP
4. **Christopher King**, Duane Davis, Goran Dellgren, Joseph Bekkers, Michael S. Mulligan Dirk Van Raemdonck, Cynthia Gries, Vincent Valentine, Vera von Dossow, Bad Oeynhausen, Dominik Hoecter, Eric E.C. de Waal, Nandor Marczin, Andre Simon. International Consensus Recommendations for Anesthetic and Intensive Care Management of Lung Transplantation An EACTA, SCA, ISHLT, ESOT, ESTS, and AST approved document Surgical Complications. *JHLT* 2021 (in press)

REVIEWS and CASE REPORTS

1. **Khangoora V, King CS, Shlobin OA.** Managing pulmonary hypertension: How to select and facilitate transplantation. *Curr Opin in Transpl* 2022; 27(3): 169-176.
2. **Steven D. Nathan,** Juergen Behr, Vincent Cottin, Lisa Lancaster, Peter Smith, CQ Deng, Natalie Pearce, Heidi Bell, Leigh Peterson, Kevin Flaherty. Study Design and Rationale for the TETON Phase 3, Randomized, Controlled Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis. Accepted to *BMJ Open Res* 06/17/2022
3. Kolb M Orfanos S, Lambers C, Flaherty K, Masters A, Lancaster L, Silverstein A, **Nathan SD.** The antifibrotic effects of inhaled Treprostinil. *Adv Ther.* 2022 Jul 3. doi: 10.1007/s12325-022-02229-8.
4. Singh N, Dorfmuller P, **Shlobin OA,** Ventetuolo CE. Group 3 Pulmonary Hypertension: From bench to bedside. *Circulation Research* 2022; 130:1404-1422. DOI: 10.1161/CIRCRESAHA.121.319970
5. Sergio Harari, Athol U. Wells, Wim A. Wuyts, **Steven D. Nathan,** Klaus-Uwe Kirchgaessler, Monica Bengus Jürgen Behr. Selective use of the six-minute walk test as a primary endpoint in interstitial lung disease clinical trials. accepted to *European Respiratory Review* 06/14/2022
6. Lida P. Hariri, Anja C. Roden, Jonathan H. Chung, Sonye K. Danoff, Diana C. Gomez Manjarres, Matthew Hartwig, Fayez Kheir, **Christopher King,** Maryl Kreider, David A. Lynch, Joshua Mooney, Ashok Muniappan, Jeffrey Myers, Luca Paoletti, Rishi Raj, Zeenat Safdar, Sally Suliman, Krishna Thavarajah, David J. Lederer, Rick Rudell, Pauline Bianchi, Barry Shea, Brett Ley. The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation. Accepted to the *Annals ATS.*
7. **Ahmed K, Pluhacek JL, Brown AW.** Ex Vivo Lung Perfusion: A Review of Current and Future Application in Lung Transplantation. *Pulm Ther* <https://doi.org/10.1007/s41030-022-00185-w>
8. **Ahmad K, Khangoora V, Nathan SD.** Lung Disease Related Pulmonary Hypertension. *Cardiol Clin.* 2022 Feb;40(1):77-88. doi: 10.1016/j.ccl.2021.08.005. PMID: 34809919
9. Shiva R. Ambardar, Stephanie Hightower, Nikhil Huprikar, Kevin Chung , **Anju Singhal** , Jacob Collen. Post-COVID-19 Pulmonary Fibrosis: novel sequelae of the current pandemic. *J Clin Med*
10. Bradley A. Maron, Steven H. Abman, C. Greg Elliott, Robert P Frantz, Rachel K. Hopper, Evelyn M. Horn, Mark R. Nicolls,, **Oksana A. Shlobin,** Sanjiv J. Shah, Gabor Kovacs, Horst Olschewski, Erika B. Rosenzweig. Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances e pub *Am J Res and Crit Care Med.*
11. **Khangoora VS, Shlobin OA.** The Evolving spectrum of treatment for CTEPH. *Curr Opinion in Pulm Med* 2020 Sep; 26(5):406-413.
12. Shiva R. Ambardar ,Stephanie Hightower, Nikhil Huprikar , Kevin Chung , **Anju Singhal,** Jacob Collen. Post-COVID-19 Pulmonary Fibrosis: novel sequelae of the current pandemic. *Journal of Clinical Medicine.*
13. **King CS,** Mannem H, Kukreja J, **Aryal S, Tang D,** Singer JP, Bharat A, Behr J, **Nathan SD.** Lung Transplantation of COVID-19 patients: **How I do it.** *Chest.* 2022 Jan;161(1):169-178. doi: 10.1016/j.chest.2021.08.041. Epub 2021 Aug 19.
14. Aaron Yaras, Stephen C. Mathai, **Steven D. Nathan,** Hilary M. DuBrock, Kellie Morland, Natalie Anderson, Mark Kosinski, Xiaochen Lin, Peter Classi. Considerations when Selecting Patient-Reported Outcome Measures for Assessment of Health-Related Quality of Life in Patients with Pulmonary Hypertension: A Systematic Review. Accepted to *Chest* 08/06/2022.

BOOK CHAPTERS AND BOOKS

1. **Khangoora V**, Nunes H, **Shlobin OA**. Sarcoidosis Associated Pulmonary Hypertension. Sarcoidosis Associated Pulmonary Hypertension. In Bonella F, Culver DA & Israel-Biet D, eds. Sarcoidosis (ERS Monogram) 2021. DOI 10.1183/2312508X.10032920
2. **Shambhu Aryal, Vikramjit Khangoora, Steven D Nathan**. Lung Transplantation For Pulmonary Hypertension. For Encyclopedia of Respiratory Medicine
3. **Aryal S, Ahmad K, Nathan SD**. Group 3 PH: Clinical Features and Treatment: For Encyclopedia of Respiratory Medicine, 2nd Edition Medicine being published by Elsevier. <https://doi.org/10.1016/B978-0-12-801238-3.11655-1>
4. Baris A, Basyigit I, **Nathan SD**. Idiopathic Interstitial Pneumonias. For the book, United Airways: from the nostrils to the alveoli. To be published by Springer publishing company. Submitted Dec 22nd, 2020.
5. Yau P, Lat T, **Shlobin OA**, Malave A, Levine DJ. Pulmonary vascular disease and transplant in advanced lung diseases (Chapter 24). Pulmonary Vascular Disorders. Edited by Carbone RG, Puppò F and Tapson VF (Nova Medicine & Health 2021).
6. **Shambhu Aryal**, Vikas Pathak. A Clinical Manual of Sarcoidosis. Nova Science Publishers. April 12, 2022
7. **Shambhu Aryal**. Chapter 12. Lung Transplantation for Pulmonary Sarcoidosis. For the Book, A Clinical Manual of Sarcoidosis. Published by Nova Science Publishers. April 2022
8. **Anju Singhal, Oksana Shlobin**. Chapter 3. Pulmonary Hypertension in Patients with Sarcoidosis For the Book, A Clinical Manual of Sarcoidosis. Published by Nova Science Publishers. April 2022

Editorials

1. Chandel A, **Nathan SD**. Piecing together the bigger picture: Idiopathic pulmonary fibrosis in Australia and beyond. *Respirology*. 2022 Jan 17. doi: 10.1111/resp.14209. Online ahead of print. PMID: 35037339

LETTERS

1. **Nathan SD**. Inhaled Treprostinil after Initial Clinical Worsening: To Continue or Not to Continue, That's the Question. Response letter. *Am J Respir Crit Care Med*. 2022 May 15;205(10):1251-1252. doi: 10.1164/rccm.202201-0081LE. PMID: 35353003
2. Amisha V. Barochia, Scott D. Barnett, Nargues Weir, Stewart J. Levine, **Steven D. Nathan**. Reply: Not all HDL particles are equal in idiopathic pulmonary fibrosis. *European Respiratory Journal* 2022 59: 2200151; DOI: 10.1183/13993003.00151-2022
3. **El-Kersh K, Nathan SD**. Categorizing pulmonary hypertension: the conundrum of the continuum. Submitted to *Lancet Res Med* 7/26/2022

MEDIA

ORIGINAL RESEARCH ABSTRACTS & PRESENTATIONS TO INTERNATIONAL MEETINGS

ISHLT 2022

1. CMV infection in heart and lung recipients after COVID mRNA vaccines to ISHLT. Presented at ISHLT, April 2022
2. Sean Agbor-Enoh, Hyesik Kong, Temesgen Andargie, Moon Jang, Pali Shah, **Steven D. Nathan**. Is acute rejection an acute disease or an exacerbation of an early post-transplant disease? Presented at ISHLT, April 2022
3. **Alan Nyquist, Vikramjit Khangoora, Oksana Shlobin, Shambhu Aryal, Christopher King, Anju Singhal, Kareem Ahmad, A. Whitney Brown, Steven D. Nathan**. Transplantation of Occult Signet Ring Cell Carcinoma Mimicking Pulmonary Venous-occlusive Disease. Presented at ISHLT, April 2022
4. **Alan Nyquist, Shambhu Aryal, Adam Cochrane, Margaret Fregoso**. Successful Use of Belatacept in Lung Transplant Recipients for Unique Indications. Presented at ISHLT, April 2022
5. Ananth V. Charyalleana L. Ponor, **Adam Cochrane**, Deborah Levine, Mary Philogene, Yi-Ping Fu, Moon K. Jang, Hyesik Kong, Pali Shah, Joby Matthews, Helen Luikart, Kiran K. Khush, Gerald Berry, Charles Marboe, Aldo Iacono, Jonathan B. Orens, **Steven D. Nathan**, Sean Agbor-Enoh. Restrictive Allograft Syndrome patients have higher Cell-free DNA Assessed Allograft Injury Prior to Diagnosis of Chronic Lung Allograft Dysfunction. Presented at ISHLT, April 2022
6. R. Meda, S. Fu, K. Yu, A. Charya¹, H. Kong, M. K. Jang, T. Andargie, W. Park, J. Lee, I. Tunc, G. J. Berry, C. Marboe, P. D. Shah, **S. D. Nathan**, M. B. Keller⁹, S. Agbor-Enoh. Comparative Performance Analysis Of Donor-Derived Cell-free DNA To Detect Acute Rejection In Single And Double Lung Transplant Recipients. Presented at ISHLT, April 2022
7. H. Kong, M. Jang, T. Andargie, W. Park, J. Lee¹, A. Charya, I. Tunc, G. J. Berry, C. Marboe⁴, P. D. Shah, **S. D. Nathan**, M. B. Keller, S. Agbor-Enoh. Absolute versus percent of donor-derived cell-free DNA to detect lung transplantation rejection. Presented at ISHLT, April 2022
8. Extended Cold Preservation Times Are Not Associated with Increased Post-Transplant Mortality After Ex Vivo Lung Perfusion (EVLP) at a Dedicated Facility Using a Centralized Lung Evaluation System (CLES). Presented at ISHLT, April 2022
9. Increasing Lung Transplant Availability with Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated Facility and a Centralized Lung Evaluation System (CLES): 3-Year Outcomes. Presented at ISHLT, April 2022

ATS 2022

1. **Christopher S. King, Jaskirat Saini, Vikramjit Khangoora, Shambhu Aryal, Anju Singhal, Alan Nyquist, Kareem Ahmad, A. Whitney Brown, Jamie Kennedy, Mitchell Psotka, Steven D. Nathan, MD, Oksana A Shlobin**. Long Term Follow-up of Pulmonary Arterial Hypertension Patients Managed with Oral Treprostinil. Presented at ATS 2022.
2. **Christopher S. King, Mehul Desai, James Lantry, Brad Lee, Sean Amedeo, Steven D. Nathan**. Fostamatinib Therapy in Severe ARDS Requiring Extracorporeal Membrane Oxygenation (ECMO) Support. Presented at ATS 2022..
3. **Abhimanyu Chandel; Antonia Pelligrini; Benham Tehrani, Claire Collins; Shourjo Chakravorty; Vikramjit Khangoora, Shambhu Aryal, Anju Singhal, Alan Nyquist, Oksana A. Shlobin, Christopher S. King, Steven D. Nathan**. Six-minute Walk Test Distance as a Simple Non-

invasive Risk Stratification Tool for Prediction of Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. Presented at ATS 2022.

4. **Abhimanyu Chandel; Antonia Pellegrini; Benham Tehrani, Claire Collins; Shourjo Chakravorty; Vikramjit Khangoora, Shambhu Aryal, Anju Singhal, Alan Nyquist, Oksana A. Shlobin, Christopher S. King, Steven D. Nathan.** Low Cardiac Index as an Under Recognized Manifestation of Idiopathic Pulmonary Fibrosis. Presented at ATS 2022.
5. **Christopher S. King, Rose Ignacio, Elizabeth Freheit, Shambhu Aryal, Vikramjit Khangoora, Anju Singhal, Alan Nyquist, A. Whitney Brown, Oksana A. Shlobin, Kevin Flaherty, Steven D. Nathan.** Hospitalization Rates and Association with Outcomes In Various Interstitial Lung Diseases: An Analysis of the Pulmonary Fibrosis Foundation (PFF) Patient Registry. Presented at ATS 2022.
6. Durwood W Moore, Jorge G Fernandez Davila, Sarah Bui, **Ashely C Collins, Steven D Nathan,** Luis R Rodriguez, Geraldine M Grant. BAX Inhibitor 1 (BI-1) promotes survival against ER stress in idiopathic pulmonary fibrosis. Presented at ATS 2022.
7. Jorge G Fernandez Davila, Durwood W Moore, Jawad Khan, **Ashely C Collins, Steven D Nathan,** Luis R Rodriguez, Geraldine M Grant, Jeffrey L Moran. Fibrotic Lung Matrix Derived Hydrogels as an in-vitro 3D Platform for Drug Discovery in Idiopathic Pulmonary Fibrosis. Presented at ATS 2022.
8. Jeffrey R. Strich, Seth Warner, Xin Tian, Rui Miao, Marcos Ramos-Benitez¹, Robert Reger, Mala Chakraborty, Susan Wong, Ankit Saxena, Philip J McCoy, Yogendra Kanthi, Daniel S. Chertow, Anthony F. Suffredini, **Steven D. Nathan,** Richard W. Childs. Fostamatinib Reduces Innate Neutrophil Activation in Hospitalized Patients with COVID-19. Presented at ATS 2022.
9. **Abhimanyu Chandel, A. Claire Collins, Kareem Ahmad, Shambhu Aryal, , Christopher S. King, Steven D. Nathan.** Vocal Capacity as a Surrogate for Vital Capacity in patients with Interstitial Lung Disease. Presented at ATS 2022.
10. Robert Baughman; Jeffrey Stewart, **Kareem Ahmad;** P Fernandes⁴, Ed Parsley, Parag Shah, **Steven D. Nathan.** Phase-2 Trial of INOpulse in Patients with Sarcoidosis associated Pulmonary Hypertension (SAPH) Requiring Supplemental Oxygen. Presented at ATS 2022.
11. Waxman A, Restrepo R, Thenappan T, Engel P, Bajwa A, Ravichandran A, Feldman J, Case A, Smith P, Deng CQ, Shen E, Tapson V, **Nathan SD.** Long-term effects of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease: the INCREASE study open-label extension. Presented at ATS 2022.

AST 2022

1. A Luxon, F Latif, **S Aryal,** D Brennan, M Flattery, M. Cooper. Impact of COVID-19 on Transplant Professionalism. Presented at AST June, 2022 as a poster presentation. Awarded poster of distinction.

ESC 2022

1. Frantz RP, **Shlobin OA,** Raina A, Wu B, Broderick M, Classi P, Sketch MR. Change in REVEAL Lite 2 and COMPERA 2.0 risk status in patients with pulmonary arterial hypertension initiating oral treprostinil on dual background therapy: a retrospective chart review (podium presentation).

ERS 2022

1. Jürgen Behr, Wim Wuyts, Harold Haller, Katerina Samara, Klaus-Uwe Kirchgässler, Frank Gilberg, **Steven D. Nathan**. Efficacy of pirfenidone in patients with advanced IPF. To be submitted to ERS 2022
2. **Steven D. Nathan**, Lisa Lancaster, Kevin Flaherty, Jürgen Behr, Vincent Cottin, Peter Smith, CQ Deng, Natalie Pearce, Heidi Bell, Leigh Peterson. Study Design and Rationale for the TETON Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis. To be submitted to ERS.
3. **Nathan SD**, Waxman A, Argula R, Rajagopal S, Johri S, De La Zerda D, McGlothlin D, Smith P, Deng CQ, Miceli M, Tapson V, Waxman A. Inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease and its effects on clinical worsening in the INCREASE study open-label extension. To be submitted to ERS

PVRI 2022

1. **Nathan SD**, Tapson VF, Levine D, Rischar F, Cassady S, DuBrock HM, Tarver J III, Smith P, Deng CQ, Shen E, Waxman AB. The importance of early treatment with inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease: a post-hoc analysis of the INCREASE open-label extension. Submitted to PVRI 2022.

CHEST 2022

1. R Sagar, **SD Nathan**, M Chakinala, J Joshua, S Gupta, B Trzaskoma, J Ko, L Lancaster. Post-hoc analysis of clinical characteristics and outcomes in patients with mild/moderate idiopathic pulmonary fibrosis (IPF) by pulmonary vascular phenotype. Submitted to Chest 2022
2. Waxman A, Elwing J, Melendres-Groves L, Risbano M, Lenneman A, Tapson VF, Shen E, Smith P, Deng C, **Nathan SD**. Long-term safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease in the INCREASE open-label extension. Submitted to Chest 2022
3. **Christopher S. King**, Kevin R. Flaherty, Marilyn K. Glassberg, Lisa Lancaster, Ganesh Raghu, Jeffrey J. Swigris, Rahul G. Argula, Rosemarie A. Dudenhofer, Neil A. Ettinger, Jeremy Feldman, Shilpa Johri, P Fernandes, Ed Parsley, Parag Shah, **Steven D. Nathan**. Subgroup analysis of iNOpulse in patients with Fibrotic Interstitial Lung Disease Requiring Supplemental Oxygen: a case for early therapy. Submitted to Chest 2022
4. **Dawoud Seraj, Oksana A. Shlobin, Vikramjit Khangoora, Shambhu Aryal, Anju Singhal, Christopher Thomas, Alan Nyquist, Steven D. Nathan, Christopher King**. Use of Prostanoids for Severe Group 3 Pulmonary Hypertension: Real World Experience from a Tertiary Care Center. Submitted to Chest 2022
5. **Nyquist A, Aryal A, King C, Schreffler M, Chun J, Fregoso M, Shlobin OA, Khangoora V, Singhal A, Thomas C, Brown AW, Nathan SD**. Assessment of Outcomes in Lung Transplant Recipients after COVID-19 Infection and the Utility of Vaccines, Outpatient Treatments, and Inpatient Interventions. Submitted to Chest 2022
6. Abhimanyu Chandel, **Jack Diviney, Antonia Pelligrini, Shambhu Aryal, Vikramjit Khangoora, Oksana A. Shlobin, Alan Nyquist, Anju Singhal, Christopher Thomas, Christopher King, Steven D. Nathan**. Derivation and validation of a simple multidimensional score for the identification of co-existing pulmonary hypertension in idiopathic pulmonary fibrosis. Submitted to Chest 2022

7. **Alan Nyquist, Johanna Coughlin**, Haresh Mani, Yasmine Assadipour, Paul Butros, Behnam Tehrani, Hazel Bowen-Wright, **Oksana A. Shlobin**. An Adrenocortical Adenoma Hiding Behind the Diagnosis of Pulmonary Hypertension. Submitted to Chest 2022
8. **Alan Nyquist, Christopher King, Anju Singhal**, Haresh Mani, Kristen Bussa, Mary Maydosz, Amy Thatcher, **Anne Whitney Brown**, Disseminated Invasive Aspergillus Masquerading as Amiodarone Induced Thyrotoxicosis. Submitted to Chest 2022

ID week

1. Seth Warner, Rui Miao, Marcos J. Ramos-Benitez, Xin Tian, Robert Reger, Peter D. Burbelo⁵, Yogendra Kanthi, Jeffrey I. Cohen, Anthony F. Suffredini, Steven D. Nathan, Richard W. Childs, Daniel S. Chertow¹, Jeffrey R. Strich. ISARS-CoV-2 Antibody Levels Associate with Neutrophil Activation. Submitted to ID week.

TALKS:

1. What's new in IPF? South African Thoracic Society meeting. Cape Town, South Africa, May 6th, 2022. (Steven Nathan)
2. The role of anti-fibrotics in ILD. South African Thoracic Society meeting. Cape Town, South Africa, May 7th, 2022. (Steven Nathan)
3. Sarcoid-associated pulmonary hypertension. South African Thoracic Society meeting. Cape Town, South Africa, May 6th, 2022. (Steven Nathan)
4. Management of group 3 pulmonary hypertension. South African Thoracic Society meeting. Cape Town, South Africa, May 6th, 2022. (Steven Nathan)
5. Early postoperative challenges in the management of the lung transplant recipient. South African Thoracic Society meeting. Cape Town, South Africa, May 6th, 2022. (Steven Nathan)
6. What COVID-19 taught us. South African Thoracic Society meeting. Cape Town, South Africa, May 7th, 2022. (Steven Nathan)
7. Pulmonary Vascular Year in Review. ISHLT 2022 (Chris King)
8. Improving Quality of Lung transplant Care: Survival is only the Beginning 4/29/22 ISHLT Meg Fregoso Co- Chair
9. Session chair Rookies and Sages: The International PH Challenge. ISHLT 2022 (Oksana Shlobin)
10. SICK BY ASSOCIATION: THE PULMONARY VASCULATURE IN CHRONIC LUNG DISEASES (session chair)
11. Sick by association: the pulmonary vasculature in chronic lung disease. Session chair. ATS 2022 (Oksana Shlobin).
12. Hospitalizations in Various ILDs: An Analysis of the PFF Registry. ATS 2022 (Chris King)
13. Inhaled Treprostinil in PH due to ILD. Plenary session ATS May 17th, 2022.

Papers Laid to Rest



1. **Nathan S.D.**, Johri S, Ardiles T, Emami S, Benza R, Miksa A, Alvarez R.A, Gawri K, Ettinger N, Youssef J, Sahay S, Jareugi-Peredo L, Shifren A, Mehta S, Guillamet R, Stewart J, Case A, Gillies H, Shah P, Edmonds A, Fernandes P, Glassberg M.K. An observational cohort study of pulsed inhaled nitric oxide in 175 patients with hypoxemia due to COVID-19. Submitted to Thorax 08/02/2020. Revisions rejected by BMJ Open Res Research 04/16/2020.
2. Brown, AW, Bowen MA, King CS, Nathan SD. Promising Results with Elexacaftor/Tezacaftor/Ivacaftor Use in Cystic Fibrosis Patients with Advanced Lung Disease: Beyond the Clinical Trial Inclusion Criteria. Submitted to NEJM 1/22/2020
3. Yeo J, Chen T, Crawford EL, Zhang X, Khuder S, Levin A, Nana-Sinkam P, Massion PP, Arenberg DA, Midthun D, Mazzone PJ, **Nathan SD**, Wainz R, Silvestri G, Tita J, Willey JC. A COPD classifier based on targeted next generation sequencing analysis of genome maintenance genes in normal airway epithelial cells. submitted to Am J Respir Crit Care Med.
4. Rodriguez LR, Beuschel RT, Bui S, Sobieski BH, Kaler MA, Barochia AV, Alqawba M, Bang E, Fernandez-Davila J, Kukudzhanova O, Prativadhi A, Shazer T, Sheikh U, Post B, Cannon B, Lemma M, Seto D, Diawara N, Levine SJ, Nathan SD, Grant G. Analysis of Mitochondrial Copy Number in Peripheral Blood of IPF Patients Elucidates Correlation between Mitochondrial Chromosome Gene Expression and Disease Severity. For submission to Am J Respir Crit Care Med.
5. Rapid High Dose Hep B vaccination prior to transplant-MB/AWB ISHLT abstract. MB ISHLT podium presentation, manuscript in preparation. Target research communication to J Heart Lung Transplant—declined initially and re-submitted as research letter (rejected from JHLT x 2, Summer 2020)
6. **Nathan SD**, Badesh DB, Elliott CG, Granton JT, Hansdottir S, Ishizawar DC, Feldman J, Ivy DD, Schilz RJ, **Schlegel L**, Shapiro SM, Sood N, Wirth JA, White J. Safety and feasibility of oral treprostinil to parenteral prostanoid transition: a multicenter analysis. Submitted to Pulmonary Circulation-rejected. **Submitted to Scientific Reports 6/17/2019.**
7. Grant G, Beuschel RT, Davial JF, Bui SN, Battle E, Lemma M, Nathan SD, Rodriguez L Isolation of Primary Fibroblasts by 45-minute Differential Binding. Submitted to MethodsX 8/6/2019
8. **Melissa A. Bowen, MPH, BSN, RN¹, Quyen Duong, RRT¹**, Cheryl Russell, RRT¹, Gerilynn Connors, BS, RRT¹, **A. Claire Collins, MS¹**, Rabih Halabi, MD¹, **Christopher S. King, MD¹, A. Whitney Brown, MD¹** PROMISING OUTCOMES AND IMPACT OF A CF SPECIFIC PULMONARY REHABILITATION PROGRAM. Rejected from J of CF in Summer 2020, revising for Respiratory Care (AWB to update) laid to rest 03/24/2021
9. Brown, AW, Bowen MA, King CS, Nathan SD. Promising Results with Elexacaftor/Tezacaftor/Ivacaftor Use in Cystic Fibrosis Patients with Advanced Lung Disease: Beyond the Clinical Trial Inclusion Criteria. Rejected from NEJM & Blue Journal 2020. Anju is

updating data for resubmission as longer term study for J Heart Lung transplant. laid to rest
03/24/2021